The in vivo translocation of nanoemulsions (NEs) was tracked by imaging tools with an emphasis on the size effect. To guarantee the accurate identification of NEs in vivo, water-quenching environment-responsive near-infrared fluorescent probes were used to label NEs. Imaging evidence confirmed prominent digestion in the gastrointestinal tract and oral absorption of integral NEs that survive digestion by enteric epithelia in a size-dependent way. In general, reducing particle size leads to slowed in vitro lipolysis and in vivo digestion, a prolonged lifetime in the small intestine, increased enteric epithelial uptake, and enhanced transportation to various organs. Histological examination revealed a pervasive distribution of smaller NEs (80 nm) into enterocytes and basolateral tissues, whereas bigger ones (550, 1000 nm) primarily adhered to villi surfaces. Following epithelial uptake, NEs are transported through the lymphatics with a fraction of approximately 3–6%, suggesting a considerable contribution of the lymphatic pathway to overall absorption. The majority of absorbed NEs were found 1 h post administration in the livers and lungs. A similar size dependency of cellular uptake and transmonolayer transport was confirmed in Caco-2 cell lines as well. In conclusion, the size-dependent translocation of integral NEs was confirmed with an absolute bioavailability of at least 6%, envisioning potential applications in oral delivery of labile entities.Keywords: drug delivery; environment-responsive; in vivo fate; nanoemulsions; nanoparticles; oral; particle size;

The nose-to-brain pathway has been proven to be a shortcut for direct drug delivery to the brain. However, whether and to what extent nanoparticles can be delivered through this passage is still awaiting validation with evidence. In this study, nose-to-brain transportation of nanoparticles is tracked via fluorescence bioimaging strategies using nanoemulsions (NEs) as model carriers. Identification of NEs in biological tissues is based on the on → off signal switching of a new type of environment-responsive embedded dyes, P2 and P4, and two conventional probes, DiR and coumarin-6 (C6), are embedded to represent the cargoes. Evidence for the translocation of NEs was collected either via live imaging or ex vivo histological examination in rats after nasal administration. Results suggest that NEs with a particle size of about 100 nm, either naked or coated with chitosan, have longer retention duration in nostrils and slower mucociliary clearance than larger ones. P2 signals, representing integral NEs, can be found in mucosa and trigeminal nerves for all size groups, whereas only weak P2 signals are detected in the olfactory bulb for chitosan-coated NEs of 100 nm. Confocal microscopy further confirms the translocation of integral 100 nm NEs in nasal mucosa and along the trigeminal nerve in decremental intensity. Weak signals of the P4 probe, also representing integral NEs, can be detected in the olfactory bulb but few in the brain. NEs as large as 900 nm cannot be transported to the olfactory bulb. However, the DiR or C6 signals that represent the cargoes can be found in significant amounts along the nose-to-brain pathway and finally reach the brain. Evidence shows that integral NEs can be delivered to the olfactory bulb, but few to the brain, whereas the cargoes can be released and permeated into the brain in greater amounts.

•Nanocrystals are unique delivery systems with drug loading up to 100%.•Nanocrystals made from a definite drug differ in their performance.•Experience obtained from specific nanocrystals cannot be extrapolated to others.•Bioimaging of integral nanocrystals is highly challengeable.•Hybrid nanocrystal is valuable in exploring the in vivo fate of nanocrystals.There has been significant research interest in, and development of, nanocrystals in recent years for the delivery of poorly water-soluble drugs via various routes. However, there is a common misinterpretation of nanocrystallization as an approach to modulate, and more specifically to enhance, the dissolution of drug crystals. Nevertheless, it is possible for nanocrystals to interact with biological tissues because nanocrystals can survive for a longer duration in vivo compared with solution counterparts. Therefore, understanding the in vivo fate of nanocrystals and determining its contribution to efficacy is of tremendous significance for optimizing the performance of nanocrystals. Here, we critically review the general hypotheses related to the in vivo fate of nanocrystals.

•LDCs-SLNs improve the oral bioavailability of silybin by 5–7 times in comparison with a fast-release formulation.•LDCs might be broken down in the GI tract and within enterocytes to release silybin, which is then transported to the circulation.•The contribution of absorption of integral SLNs via the M cell pathway is negligible to the bulk bioavailability•Longer lipid chains create more steric hindrance and slow degradation and biodistribution.Lipid-drug conjugates (LDCs) of a poorly soluble and poorly permeable drug silybin (SB) and lipids with different chain lengths (6C, 12C, 18C) are synthesized and formulated into solid lipid nanoparticles (SLNs). The in vivo fate of LDCs as well as SLNs is investigated by tracking either SB or LDCs or SLNs. LDCs are prone to be hydrolyzed by lipases either in simulated gastrointestinal media or in Caco-2 cell lines in a lipid chain length-dependent mode. The oral bioavailability of SB is enhanced by 5–7-fold in comparison with a fast-release formulation. No integral LDCs are detected in plasma confirms the readily degradable nature of LDCs. The absorption of LDCs by enteric epithelia and subsequent transportation into circulation might play a leading role in absorption enhancement, whereas the contribution of then M-cell pathway is not as remarkable. A shorter lipid chain favors earlier lipolysis and faster absorption along the intestine-to-circulation path.LDCs-containing SLNs can be degraded to release LDCs, which are then taken up by enterocytes, further broken down to SB, and finally transported to systemic circulation. This enterocyte-to-portal vein route accounts for a major part of enhanced oral bioavailability, whereas the contribution of the M cell/lymphatics route is not as remarkable.Download high-res image (206KB)Download full-size image

Although glucan microparticles (GMs) can be efficiently taken up and transported by M cells, their subsequent accumulation in lymphatic tissues of sub-follicle-associated epithelia (FAE) in Peyer's patches might present a barrier to the oral delivery of insulin by GMs into the systemic circulation. The goal of this study is to weigh the potential of GMs as carriers for oral delivery of systemic therapeutics using insulin (INS) as a model drug. INS is encapsulated into the inner cavities of GMs by repeated soaking in INS solution at acidic pH values and switching to an isoelectric pH of 5.6 to precipitate INS. To immobilize INS, a thermosensitive poloxamer 407 (P407) gel is introduced into the interior of GMs. Interiorly thickened GMs show significantly decreased in vitro release and well protected INS stability against enzyme-enriched media, highlighting the importance of thickening with P407 gels. A mild and prolonged hypoglycaemic effect is achieved in both normal and diabetic rats for a duration of at least 20 h with pharmacological bioavailability as high as about 9–10%. Lymphatic transportation of GMs is investigated by labelling with a near-infrared water-quenching fluorescent probe in a conscious mesentery lymphatic duct cannulation rat model following oral administration. GMs appear in lymph within the first 2 h, peak at around 6 h and slow down after 10 h with a cumulative amount of over 8% in 24 h. The high correlation between lymphatic transportation and pharmacological bioavailability implies that GMs are principally absorbed via the lymphatic route. An in vitro study on phagocytosis by macrophages confirms the easy and fast uptake of GMs by J774A.1 cell lines with as many as over 10 particles within the cytoplasm of a single cell. Intracellular pharmacokinetics indicates robustness and persistent residence of GMs within the cells. Little effect on cell viability and tight junctions was observed in Caco-2 cell models. It is concluded that GMs are mainly absorbed via the lymphatic route and show potential as carriers for oral delivery of labile therapeutics, though with limited bioavailability due to the sub-FAE residence barriers.

Whether and to what extent solid lipid nanoparticles (SLNs) can be absorbed integrally via oral delivery should be clarified because it is the basis for elucidation of absorption mechanisms. To address this topic, the in vivo fate of SLNs as well as their interaction with biomembranes is investigated using water-quenching fluorescent probes that can signal structural variations of lipid-based nanocarriers. Live imaging indicates prolonged retention of SLNs in the stomach, whereas in the intestine, SLNs can be digested quickly. No translocation of intact SLNs to other organs or tissues can be observed. The in situ perfusion study shows bioadhesion of both SLNs and simulated mixed micelles (SMMs) to intestinal mucus, but no evidence of penetration of integral nanocarriers. Both SLNs and SMMs exhibit significant cellular uptake, but fail to penetrate cell monolayers. Confocal laser scanning microscopy reveals that nanocarriers mainly concentrate on the surface of the monolayers, and no evidence of penetration of intact vehicles can be obtained. The mucous layer acts as a barrier to the penetration of both SLNs and SMMs. Both bile salt-decoration and SMM formulation help to strengthen the interaction with biomembranes. It is concluded that evidence does not support absorption of intact SLNs via oral delivery.

Taking advantage of its ability to deal with exogenous pathogens, the M cell passage has proven to be the most reliable pathway for entry of particulates, thus creating opportunities for oral immunization and delivery of biomacromolecules. Albeit a well-known story, the underlying mechanisms of this pathway are not yet well understood, especially concerning direct evidence of translocation of particulates. Herein, model glucan microparticles (GMs) targeting M cells are employed to track translocation through M cell pathways as well as to various organs via the systemic circulation. GMs were first labeled with a novel kind of near-infrared fluorescent water-quenching probe through encapsulation and locking by stearin. In vivo live imaging indicates prolonged residence of GMs in the gastrointestinal tract for as long as 12 h. GMs are found to be gradually absorbed from the ligated ileum segment but little from the jejunum. Histological examination using confocal laser scanning microscopy (CLSM) confirms distribution of GMs to the basolateral side of the ileum through Peyer's patches. However, no detectable fluorescence can be observed in any other organs or tissues until 12 h after administration. After 12 h, GMs can be found in the liver, spleen and lung. At 24 h, GMs accumulate in these organs with approximately 2.3% of the total amount. Repeated administration for three consecutive days augments total accumulation to as high as 4.5%. By tracking GM-bound fluorescence, the particles can be accurately located in these organs. GMs can be transported across Caco-2/Raji and Caco-2/Raji/J774A.1 co-culture monolayers, but not Caco-2 monolayers, in a time-dependent manner. As observed by CLSM, GMs can be voraciously engulfed with as many as 10–15 particles per cell. Evidence of translocation of GMs indicates that GMs can be absorbed through the M cell pathway located at Peyer's patches, especially in the ileum, and translocated to reticulo-endothelial organs.

Breaking the natural barriers of cell membranes achieves fast entry of therapeutics, which leads to enhanced efficacy and helps overcome multiple drug resistance. Herein, transmembrane delivery of a series of small molecule anticancer drugs was achieved by the construction of artificial transmembrane nanochannels formed by self-assembly of cyclic peptide (cyclo[Gln-(D-Leu-Trp)4-D-Leu], CP) nanotubes (CPNTs) in the lipid bilayers. Our in vitro study in liposomes indicated that the transport of molecules with sizes smaller than 1.0 nm, which is the internal diameter of the CPNTs, could be significantly enhanced by CPNTs in a size-selective and dose-dependent manner. Facilitated uptake of 5-fluorouracil (5-FU) was also confirmed in the BEL7402 cell line. On the contrary, CPs could facilitate neither the transport across liposomal membranes nor the uptake by cell lines of cytarabine, a counterevidence drug with a size of 1.1 nm. CPs had a very weak anticancer efficacy, but could significantly reduce the IC50 of 5-FU in BEL7402, HeLa and S180 cell lines. Analysis by a q test revealed that a combination of 5-FU and CP had a synergistic effect in BEL7402 at all CP levels, in S180 at CP levels higher than 64 μg mL−1, but not in HeLa, where an additive effect was observed. Temporarily, intratumoral injection is believed to be the best way for CP administration. In vivo imaging using 125I radio-labelled CP confirmed that CPNPTs were completely localized in the tumor tissues, and translocation to other tissues was negligible. In vivo anticancer efficacy was studied in the grafted S180 solid tumor model in mice, and the results indicated that tumor growth was greatly inhibited by the combinatory use of 5-FU and CP, and a synergistic effect was observed at CP doses of 0.25 mg per kg bw. It is concluded that facilitated transmembrane delivery of anticancer drugs with sizes smaller than 1.0 nm was achieved, and the synergistic anticancer effect was confirmed both in cell lines and in vivo through the combinatory use of 5-FU and CP.

One of the biggest challenges in bioimaging of nanoparticles is how to identify integral particles from bulk signals of probes. Signals of free probes are always mistakenly counted into total signals of particles. In this study, in vivo fate of intravenous polymeric micelles (PMs, mPEG2.5k–PDLLA2.5k) was explored using a highly sensitive near-infrared environment-responsive fluorescent probe. This probe is able to emit fluorescence when embedded in nanocarriers but quench spontaneously and absolutely upon release into water, based on the aggregation-caused quenching effect, which means that the interference generated by free probes can be completely diminished. Analysis of blood-borne fluorescence reveals rapid clearance of PMs from blood following a tricompartmental pharmacokinetic model. Live imaging shows pervasive distribution of PMs throughout the body, and a tendency of accumulation to extremities with fluorescence density 3–5 times higher than the trunk. Ex vivo examination reveals that most PMs are found in vital organs following an order of lung > liver > spleen > heart > kidney in concentration, but an order of liver > lung > spleen > heart ≈ kidney in total amount. The distribution to other organs and tissues is even lower, and to brain, negligible. It is concluded that the biodistribution of PMs to vital organs and extremities warns of potential toxicity and can be translated to explain the toxicity of its commercial counterpart with similar chain lengths.Keywords: biodistribution; bioimaging; environment-responsive; fluorescent probes; long-circulating; PEG−PLA; polymeric micelles; stealth;

•Gelatin-thickening enhances stability of bilosomes against lyophilization stress.•Freeze-dried probilosomes show perfect restoring ability upon rehydration.•Probilosomes significantly enhance oral bioavailability of cyclosporine A.Formulating vesicular nanocarriers into dried precursors so as to overcome the drawbacks associated with liquid formulations is challengeable due to low efficiency of restoration. In this study, bilosomes interiorly thickened with gelatin (G-BLs) was evaluated for the ability to withstand freeze-drying stress and enhanced oral bioavailability of a model drug, cyclosporine A (CyA). The restoration efficiency of freeze-dried pro-G-BLs is investigated by comparing the particle size distribution, entrapment efficiency and morphology of the bilosomes before and after freeze-drying. Particle size and polydispersity index (PI) of pro-G-BLs after restoration was similar to that before freeze-drying, whereas freeze-dried bilosomes without gelatin thickening (pro-BLs) show irreversible damage and aggregation along with significantly increased particle size and PI after restoration. Entrapment efficiency of pro-G-BLs remains as high as 83.7%, in sharp contrast with 66.7% for pro-BLs. Pharmacokinetics in beagle dogs show improved absorption of CyA in pro-G-BLs as compared to pro-BLs, G-BLs and microemulsion-based Sandimmun Neoral®. The relative oral bioavailability of CyA-loaded pro-G-BLs, pro-BLs and G-BLs was 165.2%, 123.5% and 130.1%, respectively, with Neoral® as the reference. It is concluded that interior thickening with gelatin significantly enhanced the stability against freeze-drying stress, which as a result improves the restoring efficiency and oral bioavailability.

To achieve controlled release of integral nanoparticles by the osmotic pump strategy using nanostructured lipid carriers (NLCs) as model nanoparticles.NLCs was prepared by a hot-homogenization method, transformed into powder by lyophilization, and formulated into osmotic pump tablets (OPTs). Release of integral NLCs was visualized by live imaging after labeling with a water-quenching fluorescent probe. Effects of formulation variables on in vitro release characteristics were evaluated by measuring the model drug fenofibrate. Pharmacokinetics were studied in beagle dogs using the core tablet and a micronized fenofibrate formulation as references.NLCs are released through the release orifices of the OPTs as integral nanoparticles. Near zero-order kinetics can be achieved by optimizing the influencing variables. After oral administration, decreased Cmax and steady drug levels for as long as over 24 h are observed. NLC-OPTs show an oral bioavailability of the model drug fenofibrate similar to that of the core tablets, which is about 1.75 folds that of a fast-release formulation.Controlled release of integral NLCs is achieved by the osmotic pump strategy.

•The nanocrystals prepared was smaller than 229 nm.•Redispersion of nanocrystals powder was performed above 30 °C.•A fine in vivo–in vitro correlation was established.•Cmax and AUC improved and CL/F reduced with particle size decreased.Puerarin is widely used in clinics in China as a therapeutic agent for cardiovascular diseases by intravenous administration. Adverse drug reactions caused by cosolvents often increase the patients’ treatment burden (high drug costs and low compliance). The development of oral formulation is urgently needed and nanocrystal technique has become a preferred way to develop oral dosage form, nowadays. In this study, high pressure homogenization (HPH) was employed to prepare puerarin nanocrystals by employing SDS as the stabilizer, and redispersibility of the nanocrystals powder was also studied. The nanocrystals prepared was characterized using DLS, DSC, XRD and SEM. A preferred in vivo–in vitro correlation was also established in this study. Pharmacokinetic studies on beagle dog showed that comparing to raw puerarin powder, both of the Cmax and AUC of puerarin nanocrystals were enhanced. From the above results, we can conclude that nanocrystal technique is an efficient technology to improve the oral bioavailability of puerarin.

Environment-responsive near-infrared (NIR) aza-BODIPY dyes capable of fluorescence quenching in water were explored to visualize the in vivo fate of model lipid-based nanocarriers, solid lipid nanoparticles (SLNs). The water-quenching effect of the dyes was confirmed to be sensitive and remained stable for at least 24 h. In vitro lipolysis measured by fluorescence quenching completed within 20 min, which was in correlation with alkaline compensation results. In vivo live imaging indicated predominant digestion of SLNs within 2 h and complete digestion within 4 h, which correlated well to in vitro data. Rekindling of quenched dyes by mixed micelles was observed in vitro, but not in vivo. In sharp contrast, SLNs encapsulating another NIR dye DiR showed persistent fluorescence both in vitro and in vivo despite significant lipolysis. It was envisaged that water-quenching fluorescence dyes can be used as probes to monitor the in vivo fate of lipid-based nanocarriers.From the Clinical EditorLipid-based drug delivery systems can provide an excellent nanocarrier platform for the delivery of poorly water-soluble drugs. Nonetheless, the mechanism of oral absorption and subsequent kinetics is poorly understood. In this article, the authors studied the novel use of near-infrared (NIR) aza-BODIPY dyes to visualize the fate of these lipid-based nanocarriers. The positive finding means that this approach may be useful for in-vivo monitoring of lipid-based nanocarriers.Near-infrared fluorescent dyes (P2) encapsulated in solid lipid nanoparticles (SLN) quenched spontaneously upon contact with water after being released from SLNs. This class of water-quenching dyes could accurately report the in vivo fate of lipid-based nanocarriers through live imaging, whereas the conventional non-water-quenching dyes (DiR) provided false signals.

This study aimed to explore biotinylated liposomes (BLPs) as novel carriers to enhance the oral delivery of insulin. Biotinylation was achieved by incorporating biotin-conjugated phospholipids into the liposome membranes. A significant hypoglycemic effect and enhanced absorption were observed after treating diabetic rats with the BLPs with a relative bioavailability of 12.09% and 8.23%, based on the measurement of the pharmacologic effect and the blood insulin level, respectively; this achieved bioavailability was approximately double that of conventional liposomes. The significance of the biotinylation was confirmed by the facilitated absorption of the BLPs through receptor-mediated endocytosis, as well as by the improved physical stability of the liposomes. Increased cellular uptake and quick gastrointestinal transport further verified the ability of the BLPs to enhance absorption. These results provide a proof of concept that BLPs can be used as potential carriers for the oral delivery of insulin.From the Clinical EditorDiabetes remains a major source of mortality in the Western world, and advances in its management are expected to have substantial socioeconomic impact. In this paper, biotinylated liposomes were utilized as carriers of insulin for local delivery, demonstrating the feasibility of this approach in a rat model.Hypoglycemic effect and enhanced oral bioavailability were obtained by incorporating insulin into biotin-modified liposomal vesicles. Such novel nanocarriers presented a promising strategy to enhance the oral delivery of insulin based on two aspects: improved physical stability and transepithelial absorption by biotin receptor-mediated endocytosis.

•NLCs suspension was converted onto pellets surface using fluid-bed coating technique.•The solidified NLCs could be redispersed readily into NLC suspension with 15 min in water.•The particle size of reconstituted NLCs was significantly higher than the original NLCs.•In vitro lipolysis and pharmacokinetics were similar for NLC suspensions and solidified NLCs.There are demands to solidify nanoparticle suspensions to overcome problems associated with liquid formulations. In the present study, the liquid nanostructured lipid carriers (NLCs), which were comprised of Precirol ATO 5, Captex100, Tween-80 and fenofibrate as the model drug, was prepared by the melting-emulsification method and converted to solidified NLC pellets by fluid-bed coating technique. To achieve good coating, polyvinylpyrrolidone K17 was used as the coating polymer to entrap the NLCs. Physical characterization indicated good appearance and confirmed nonexistence of crystalline fenofibrate in the solidified NLC pellets. More than 90% NLCs could be released from the solidified NLC pellets within 15 min. The reconstituted NLCs had spherical morphology similar to the original NLCs, but had an average particle size of 227.5 nm which was significantly larger than 94.1 nm of the original ones. However, both solidified NLC pellets and original NLC suspension showed similar in vitro lipolysis profiles and similar pharmacokinetics parameters in beagle dogs. Results indicated that fluid-bed coating could be a useful tool for the solidification of NLC suspension.

A general method was described to synthesize a highly hydrophobic cyclic peptide, cyclo[LWLWLWLWLQ] where underlines indicate d-configuration of the amino acid, by a two-step solid-phase/solution synthesis strategy. The linear decapeptide was assembled by standard Boc chemistry on solid-phase and subsequently cyclized in solution with high efficiency and reproducibility. In subsequent purification by semi-preparative HPLC, 50% (v/v) DMF/H2O was employed as the solvent to overcome the difficulty of solubilization for the hydrophobic cyclic decapeptide and achieved a total yield of 30–35% with a purity of over 98%.

Meloxicam-β-cyclodextrin (ME-β-CD) inclusion complex was prepared by a fluid-bed coating technique upon solvent removal and simultaneous depositing onto the surface of nonpareil pellets and using PVP K30 as a binding agent to facilitate good coating. The resultant pellets were spherical and intact in shape with good flowability and friability. SEM analysis showed that the pellets were smooth and had a tightly coated inclusion complex layer. In vitro dissolution of the inclusion complex pellets in pH 7.4 phosphate buffer was dramatically enhanced at an ME/CD ratio of 1/1. DSC and powder X-ray diffractometry proved the absence of crystallinity in the ME/CD inclusion complexes. Moreover, Fourier transform-infrared spectrometry together with Raman spectrometry indicated that the thiazole ring of ME was possibly included in the cavity of β-CD.

Glyceryl monooleate (GMO)/poloxamer 407 cubic nanoparticles were investigated as potential oral drug delivery systems to enhance the bioavailability of the water-insoluble model drug simvastatin. The simvastatin-loaded cubic nanoparticles were prepared through fragmentation of the GMO/poloxamer 407 bulk cubic-phase gel using high-pressure homogenization. The internal structure of the cubic nanoparticles was identified by cryo-transmission electron microscopy. The mean diameter of the cubic nanoparticles varied within the range of 100–150 nm, and both GMO/poloxamer 407 ratio and theoretical drug loading had no significant effect on particle size and distribution. Almost complete entrapment with efficiency over 98% was achieved due to the high affinity of simvastatin to the hydrophobic regions of the cubic phase. Release of simvastatin from the cubic nanoparticles was limited both in 0.1 M hydrochloride solution containing 0.2% sodium lauryl sulfate and fasted-state simulated intestinal fluid with a total release of <3.0% at 10 h. Pharmacokinetic profiles in beagle dogs showed sustained plasma levels of simvastatin for cubic nanoparticles over 12 h. The relative oral bioavailability of simvastatin cubic nanoparticles calculated on the basis of area under the curve was 241% compared to simvastatin crystal powder. The enhancement of simvastatin bioavailability was possibly attributable to facilitated absorption by lipids in the formulation rather than improved release.

•Targeting the intestinal epithelia is a new strategy to enhance oral absorption of drugs.•Breakthroughs in this field will advance the development in oral drug delivery.•The transenterocytic pathway should be explored.•New insights into gut biology will enlighten development in this field.Although the oral route is the most popular and acceptable way of drug administration owing to good patient compliance and safety, oral drug delivery is faced with continuous challenges regarding poorly soluble, poorly permeable or gastrointestinally unstable drugs such as proteins and polypeptides. The overall bioavailability and therapeutic effect still needs to be further improved by innovative delivery technologies. Recently, various novel strategies, for instance using ligand-decorated carriers, have been investigated for delivery of poorly absorptive therapeutics orally. In this review, we will discuss the state of the art of ligand-mediated targeting to intestinal epithelia for oral delivery of drugs with low bioavailability.Download high-res image (240KB)Download full-size image

•LBNs are readily degradable through lipolysis by lipases.•LBNs that survive lipolysis can be translocated to various organs and tissues.•Lipid composition, particle size, surface decorations and protein corona are the main factors influencing in vivo fate of LBNs.•Lipolysis of LBNs in vivo can be visualized by labeling with environment-responsive fluorescent probes.The in vivo fate of lipid-based nanoparticles (LBNs) is essentially determined by the properties of their lipid compositions. LBNs are rapidly degraded via lipolysis wherever lipases are abundant, especially in the gastrointestinal tract. LBNs that survive lipolysis can be translocated through the circulation to reach terminal organs or tissues. Lipid composition, particle size, and surface decoration, as well as the formation of protein corona, are the main factors influencing the in vivo fate of LBNs. As we discuss here, elucidation of the in vivo fate of LBNs helps weigh the balance between lipolysis and biorecognition, and is emerging as a new field of research.

•Exploring the in vivo fate of nanoparticles is emerging as an interesting and important research topic.•It is crucial to discriminate signals of integral nanoparticles from free probes.•Environment-responsive probes can report the in vivo fate of nanocarriers by smart signal switching.•Water-sensitive fluorescent probes have been used to explore the in vivo fate of lipid nanoparticles.The biological fate of nanocarriers has yet to be fully explored, mainly because of the lack of functional tools like probes to identify integral nanocarriers in the body. Understanding their in vivo fate remains as the bottleneck to the development of nanomedicines. Bioimaging results based on conventional fluorescent or radioactive probes should be judged critically because images merely reflect bulk signals of an admixture of the nanoparticles and free probes. It is crucial to discriminate between nanocarrier-bound and free signals. This review analyzes the state-of-the-art of bioimaging of nanoparticles in vivo and highlights directions for future endeavours.

Although glucan microparticles (GMs) can be efficiently taken up and transported by M cells, their subsequent accumulation in lymphatic tissues of sub-follicle-associated epithelia (FAE) in Peyer's patches might present a barrier to the oral delivery of insulin by GMs into the systemic circulation. The goal of this study is to weigh the potential of GMs as carriers for oral delivery of systemic therapeutics using insulin (INS) as a model drug. INS is encapsulated into the inner cavities of GMs by repeated soaking in INS solution at acidic pH values and switching to an isoelectric pH of 5.6 to precipitate INS. To immobilize INS, a thermosensitive poloxamer 407 (P407) gel is introduced into the interior of GMs. Interiorly thickened GMs show significantly decreased in vitro release and well protected INS stability against enzyme-enriched media, highlighting the importance of thickening with P407 gels. A mild and prolonged hypoglycaemic effect is achieved in both normal and diabetic rats for a duration of at least 20 h with pharmacological bioavailability as high as about 9–10%. Lymphatic transportation of GMs is investigated by labelling with a near-infrared water-quenching fluorescent probe in a conscious mesentery lymphatic duct cannulation rat model following oral administration. GMs appear in lymph within the first 2 h, peak at around 6 h and slow down after 10 h with a cumulative amount of over 8% in 24 h. The high correlation between lymphatic transportation and pharmacological bioavailability implies that GMs are principally absorbed via the lymphatic route. An in vitro study on phagocytosis by macrophages confirms the easy and fast uptake of GMs by J774A.1 cell lines with as many as over 10 particles within the cytoplasm of a single cell. Intracellular pharmacokinetics indicates robustness and persistent residence of GMs within the cells. Little effect on cell viability and tight junctions was observed in Caco-2 cell models. It is concluded that GMs are mainly absorbed via the lymphatic route and show potential as carriers for oral delivery of labile therapeutics, though with limited bioavailability due to the sub-FAE residence barriers.

Taking advantage of its ability to deal with exogenous pathogens, the M cell passage has proven to be the most reliable pathway for entry of particulates, thus creating opportunities for oral immunization and delivery of biomacromolecules. Albeit a well-known story, the underlying mechanisms of this pathway are not yet well understood, especially concerning direct evidence of translocation of particulates. Herein, model glucan microparticles (GMs) targeting M cells are employed to track translocation through M cell pathways as well as to various organs via the systemic circulation. GMs were first labeled with a novel kind of near-infrared fluorescent water-quenching probe through encapsulation and locking by stearin. In vivo live imaging indicates prolonged residence of GMs in the gastrointestinal tract for as long as 12 h. GMs are found to be gradually absorbed from the ligated ileum segment but little from the jejunum. Histological examination using confocal laser scanning microscopy (CLSM) confirms distribution of GMs to the basolateral side of the ileum through Peyer's patches. However, no detectable fluorescence can be observed in any other organs or tissues until 12 h after administration. After 12 h, GMs can be found in the liver, spleen and lung. At 24 h, GMs accumulate in these organs with approximately 2.3% of the total amount. Repeated administration for three consecutive days augments total accumulation to as high as 4.5%. By tracking GM-bound fluorescence, the particles can be accurately located in these organs. GMs can be transported across Caco-2/Raji and Caco-2/Raji/J774A.1 co-culture monolayers, but not Caco-2 monolayers, in a time-dependent manner. As observed by CLSM, GMs can be voraciously engulfed with as many as 10–15 particles per cell. Evidence of translocation of GMs indicates that GMs can be absorbed through the M cell pathway located at Peyer's patches, especially in the ileum, and translocated to reticulo-endothelial organs.